Does exogenous glucose-dependent insulinotropic polypeptide (GIP) effect gastric emptying and glycaemic response to small intestinal nutrient in critically ill patients?

The effect of exogenous glucose-dependent insulinotropic polypeptide (GIP) on gastric emptying and glucose metabolism in critically ill patients

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12612000488808

Enrollment

Registered

2012-05-03

Start date

2012-04-18

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The primary objective of this study is to establish if exogenous glucose-dependent insulinotropic polypeptide (GIP) has a glucose lowering effect in critically ill patients and whether it effects gastric emptying

Interventions

Study Drug: Glucose-dependent insulinotropic polypeptide (GIP) at 4pmol.kg.min Infused intravenously at rate of 1ml/min from 0-360mins Patients will be studied on 2 consecutive days (i.e. 24 hour washout period)

Study design

Allocation

Randomised controlled trial

Intervention model

Crossover

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

Mechanically ventilated critically ill patients. Suitable for, or receiving post-pyloric nutrition. Likely to stay ventilated for at least 48 hours.

Exclusion criteria

History of diabetes Pregnancy Haemoglobin <80g/L Contraindication to enteral feeding Previous surgery to small intestine Any gastrointestinal surgery during admission

Outcome results